Federica Vacondio

List of Publications by Year
in descending order

70	2,012	212478	286692
papers	citations	28 h-index	43 g-index

73	73	73	3590
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Ephâ€“Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice. Pharmaceuticals, 2022, 15, 41.	1.7	2
2	Steps towards sustainable solid phase peptide synthesis: use and recovery of N-octyl pyrrolidone. Green Chemistry, 2021, 23, 4095-4106.	4.6	21
3	Palladium Catalyst Recycling for Heckâ€Cassarâ€Sonogashira Crossâ€Coupling Reactions in Green Solvent/Base Blend. ChemSusChem, 2021, 14, 2591-2600.	3.6	21
4	Nâ€(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. ChemMedChem, 2021, 16, 3071-3082.	1.6	6
5	A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. European Journal of Medicinal Chemistry, 2021, 225, 113786.	2.6	28
6	Development and Validation of [18f](2 S,4 R)-4-Fluoroglutamine in Multiple Myeloma Mouse Models. Blood, 2021, 138, 2674-2674.	0.6	0
7	Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. Journal of Medicinal Chemistry, 2020, 63, 1261-1280.	2.9	9
8	Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113067.	1.4	5
9	The GABAB receptor positive allosteric modulator COR659: In vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives. European Journal of Pharmaceutical Sciences, 2020, 155, 105544.	1.9	9
10	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). Journal of Clinical Lipidology, 2020, 14, 487-497.e1.	0.6	17
11	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. Journal of Medicinal Chemistry, 2020, 63, 7369-7391.	2.9	18
12	2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2020, 11, 1435-1441.	1.3	18
13	Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. European Neuropsychopharmacology, 2020, 32, 77-87.	0.3	22
14	Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3Î±-carbamoyloxy derivative with antiangiogenetic properties. European Journal of Medicinal Chemistry, 2020, 189, 112083.	2.6	5
15	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. European Journal of Medicinal Chemistry, 2019, 162, 507-524.	2.6	11
16	Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Letters, 2019, 446, 25-37.	3.2	28
17	[18f]-(2S,4R)-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma. Blood, 2019, 134, 5542-5542.	0.6	0
18	UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget, 2018, 9, 24347-24363.	0.8	28

#	Article	IF	Citations
19	Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychologicalâ€"cardiac comorbidity?. Neuroscience and Biobehavioral Reviews, 2017, 74, 444-452.	2.9	16
20	Accepting the Invitation to Open Innovation in Malaria Drug Discovery: Synthesis, Biological Evaluation, and Investigation on the Structureâ€"Activity Relationships of Benzo[b]thiophene-2-carboxamides as Antimalarial Agents. Journal of Medicinal Chemistry, 2017, 60, 1959-1970.	2.9	42
21	Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates. Psychoneuroendocrinology, 2017, 82, 155-163.	1.3	37
22	Synthesis of Novel c(AmpRGD)â€"Sunitinib Dual Conjugates as Molecular Tools Targeting the Î±_vÎ²₃ Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis. Journal of Medicinal Chemistry, 2017, 60, 248-262.	2.9	36
23	Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Proteinâ€"Protein Interaction Inhibitors Targeting the EphA2 Receptor. Journal of Medicinal Chemistry, 2017, 60, 787-796.	2.9	32
24	Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery. Journal of Medicinal Chemistry, 2017, 60, 7108-7122.	2.9	64
25	Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety. Scientific Reports, 2016, 5, 18218.	1.6	18
26	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	2.9	29
27	Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochemical Pharmacology, 2016, 99, 18-30.	2.0	6
28	Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. Scientific Reports, 2016, 6, 31046.	1.6	13
29	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. Journal of Medicinal Chemistry, 2016, 59, 1052-1067.	2.9	32
30	Potent, Metabolically Stable 2â€Alkylâ€8â€(2Hâ€1,2,3â€triazolâ€2â€yl)â€9Hâ€adenines as Adenosine A_{2A} Receptor Ligands. ChemMedChem, 2015, 10, 1149-1152.	1.6	2
31	Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. PLoS ONE, 2015, 10, e0128699.	1.1	23
32	Synthesis and preclinical evaluation of a novel, selective ¹¹¹In-labelled aminoproline-RGD-peptide for non-invasive melanoma tumor imaging. MedChemComm, 2015, 6, 2175-2183.	3.5	11
33	Peroxide-Dependent MGL Sulfenylation Regulates 2-AG-Mediated Endocannabinoid Signaling in Brain Neurons. Chemistry and Biology, 2015, 22, 619-628.	6.2	31
34	On the selection of an opioid for local skin analgesia: Structure-skin permeability relationships. International Journal of Pharmaceutics, 2015, 489, 177-185.	2.6	14
35	Î"5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€"ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324.	2.6	38
36	Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats. European Neuropsychopharmacology, 2015, 25, 2157-2169.	0.3	27

#	Article	IF	Citations
37	Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLCâ€“TOF/MS and GC/MS. Science and Justice - Journal of the Forensic Science Society, 2014, 54, 228-237.	1.3	32
38	Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EPHA2â€“ephrin-A1 Interaction. Journal of Chemical Information and Modeling, 2014, 54, 2621-2626.	2.5	13
39	Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study. ACS Medicinal Chemistry Letters, 2014, 5, 501-505.	1.3	77
40	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5290-5294.	1.0	3
41	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	2.9	53
42	Brain Pharmacokinetics of Nonâ€imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrosprayâ€Mass Spectrometry and ex vivo Binding Study in Rats. Chemistry and Biodiversity, 2012, 9, 1231-1239.	1.0	0
43	N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis and Structureâ€“Activity and Structureâ€“Property Relationships. Journal of Medicinal Chemistry, 2012, 55, 4824-4836.	2.9	48
44	Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. European Journal of Medicinal Chemistry, 2012, 48, 214-230.	2.6	11
45	Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: Steric effects of N-alkyl chain on rat plasma and liver stability. European Journal of Medicinal Chemistry, 2011, 46, 4466-4473.	2.6	20
46	Liquid chromatographyâ€mass spectrometric method for determination of the nonâ€imidazole H₃â€receptor antagonist UPR1056 in rat plasma. Journal of Separation Science, 2011, 34, 1656-1663.	1.3	2
47	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	1.1	37
48	Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience, 2010, 13, 1265-1270.	7.1	289
49	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. Journal of Medicinal Chemistry, 2010, 53, 2038-2050.	2.9	49
50	Qualitative structure-metabolism relationships in the hydrolysis of carbamates. Drug Metabolism Reviews, 2010, 42, 551-589.	1.5	56
51	Synthesis and Structureâ"Activity Relationships of N-(2-Oxo-3-oxetanyl)amides as N-Acylethanolamine-hydrolyzing Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 5770-5781.	2.9	53
52	Structureâ€“Property Relationships of a Class of Carbamateâ€Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability. ChemMedChem, 2009, 4, 1495-1504.	1.6	40
53	A Second Generation of Carbamateâ€Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity inâ€...vivo. ChemMedChem, 2009, 4, 1505-1513.	1.6	68
54	Nâ€(Anilinoethyl)amides: Design and Synthesis of Metabolically Stable, Selective Melatonin Receptor Ligands. ChemMedChem, 2009, 4, 1746-1755.	1.6	30

#	Article	IF	Citations
55	5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line. European Journal of Medicinal Chemistry, 2009, 44, 3471-3479.	2.6	38
56	2,4(5)-Diarylimidazoles as inhibitors of hNaV1.2 sodium channels: Pharmacological evaluation and structureâ€“property relationships. Bioorganic and Medicinal Chemistry, 2009, 17, 3642-3648.	1.4	23
57	Development and validation of a LCâ€“MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 200-205.	1.4	2
58	Synthesis and Stability in Biological Media of 1Hâ€imidazoleâ€1â€carboxylates of ROS203, an Antagonist of the Histamine H₃ Receptor. Chemistry and Biodiversity, 2008, 5, 140-152.	1.0	7
59	Synthesis and Quantitative Structureâ^'Activity Relationship of Fatty Acid Amide Hydrolase Inhibitors: Modulation at the N-Portion of Biphenyl-3-yl Alkylcarbamates. Journal of Medicinal Chemistry, 2008, 51, 3487-3498.	2.9	67
60	Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity. Journal of Pineal Research, 2006, 40, 259-269.	3.4	31
61	Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. Journal of Physiology, 2006, 576, 391-401.	1.3	57
62	Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. European Journal of Pharmaceutical Sciences, 2004, 23, 89-98.	1.9	13
63	Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities. Journal of Pineal Research, 2004, 36, 95-102.	3.4	39
64	Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. Bioorganic and Medicinal Chemistry, 2004, 12, 663-674.	1.4	49
65	The role of HB-donor groups in the heterocyclic polar fragment of H3-antagonists.. Il Farmaco, 2003, 58, 891-899.	0.9	9
66	pH-Partition profiles of 4-(3-oxo-1,2-benzisothiazolin-2-yl)phenyl and phenoxyalkanoic acids. Il Farmaco, 2003, 58, 989-993.	0.9	5
67	Three-Dimensional Quantitative Structureâ^'Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands:â€‰ Requirements for Subtype Selectivity and Intrinsic Activity Modulation. Journal of Medicinal Chemistry, 2003, 46, 1429-1439.	2.9	57
68	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. Drug Design and Discovery, 2003, 18, 65-79.	0.3	1
69	Structureâ€“property relationships on histamine H3-antagonists: binding of phenyl-substituted alkylthioimidazole derivatives to rat plasma proteins. Il Farmaco, 2000, 55, 239-245.	0.9	1
70	Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups. Il Farmaco, 2000, 55, 27-34.	0.9	12